Pharmaceutical Excipients: Product Knowledge, Supplier Selection, and Quality Standards

Common Types of Pharmaceutical Excipients and Their Functions

Pharmaceutical excipients are all substances other than the active ingredient in a drug formulation. Their traditional definition as "inert fillers" has evolved considerably—excipients are now recognized as essential functional components of any dosage form. According to classification frameworks such as those in the Chinese Pharmacopoeia (ChP), excipients can be categorized by source, chemical structure, intended use, dosage form, and route of administration.

Classification by function is the most practical approach in formulation development. Common categories include:

· Diluents (Fillers): Used to increase the volume or weight of a formulation. Typical examples include starch, sucrose, lactose, microcrystalline cellulose, inorganic salts, and sugar alcohols.

· Binders: Provide cohesion to powders, such as starch paste, cellulose derivatives, povidone, and gelatin.

· Disintegrants: Promote rapid tablet disintegration in vivo, including dry starch, sodium starch glycolate, crospovidone, and croscarmellose sodium.

· Lubricants and Glidants: Improve powder flow and prevent sticking, such as magnesium stearate, colloidal silicon dioxide, talc, and polyethylene glycols.

· Coating Materials: Used for taste masking, moisture protection, or controlled release, such as hypromellose and acrylic resins.

· Solubilizers and Wetting Agents: Enhance the dissolution and wetting of poorly soluble drugs, such as polysorbates and povidone.

From a functional perspective, modern excipients are no longer limited to shaping and process aids. Functional excipients—surfactants, cyclodextrins, polymers—can directly influence the solubility, dissolution rate, and bioavailability of the active ingredient, and some can even modulate absorption and distribution in vivo.

How to Select the Right Fine Chemical Supplier for Your Formulation

Supplier selection is both a technical and strategic decision in formulation development. Based on frameworks such as USP General Chapter <1083>, supplier evaluation should cover technical capability, quality system compliance, business continuity, and relationship fit.

Phase 1: Supplier Screening and Risk Assessment. The risk tolerance for evaluation depends on how critical the material is to the final product. The closer a material or service is to the finished drug, the lower the risk tolerance for its supplier. Manufacturers should perform risk-tiering of candidate suppliers, with high-risk materials (e.g., injectable-grade excipients) requiring more rigorous evaluation.

Phase 2: Document Review and Audit. Document review should include: manufacturing licenses, GMP certificates, site master files or DMF references, recent audit reports, quality management system reviews, and trend data on critical material attributes. On-site or remote audits should be conducted when necessary to verify information obtained during document review and to gain direct insight into the supplier's personnel, equipment, and facility capabilities.

Phase 3: Sample Testing and Quality Agreements. For each material supplier, testing at least three batches is recommended to evaluate whether the supplier can consistently deliver material of the quality required for the intended use. Key terms covering shipping methods, GMP requirements, change notification obligations, and deviation/complaint handling should then be formalized through contracts or quality agreements.

From a supply chain resilience perspective, the industry is increasingly emphasizing geographic diversification and manufacturing redundancy. Relying on a single geographic source for critical materials introduces significant risk. Suppliers with multi-regional manufacturing capabilities can provide business continuity if one region is disrupted.

Quality Standards for Pharmaceutical Excipients: USP, EP, and ChP Explained

The world's major pharmacopoeias—the United States Pharmacopeia (USP), the European Pharmacopoeia (EP), and the Chinese Pharmacopoeia (ChP)—all include excipient monographs, but their scope and specific requirements differ. A 2025 study noted "considerable differences" among the three pharmacopoeias regarding microbiological control requirements for excipients, along with a lack of scientific and systematic guidance standards.

Taking pharmaceutical-grade sucrose as an example, key quality requirements across pharmacopoeias compare as follows:

Conductivity is inversely proportional to sucrose purity; elevated levels indicate more water-soluble salt impurities. Solution color relates to both fat-soluble and water-soluble pigments, the latter of which may react with amino compounds and affect product safety. These differences mean that formulation companies serving global markets must adopt the corresponding pharmacopoeial standard for each registration region, rather than simply claiming "USP/EP dual compliance."

For "non-compendial excipients" without a pharmacopoeial monograph, companies must establish their own specifications. The starting point may be the supplier's specification, but an assessment is needed of whether compendial general chapters can be applied, whether acceptance criteria need adjustment, and how appropriate safety and functionality tests should be established.

The Role of Excipients in Drug Stability, Bioavailability, and Safety

Excipients influence formulation performance throughout the drug lifecycle.

In terms of stability, excipients safeguard the chemical and physical stability of active ingredients through multiple mechanisms. Antioxidants inhibit oxidative degradation, pH adjusters maintain an optimal acid-base environment, and coating materials block moisture and oxygen. However, unfavorable interactions between excipients and active ingredients can also occur and must be identified during preformulation studies.

In terms of bioavailability, excipients play a particularly critical role. The dissolution rate of poorly soluble drugs is often limited by wettability and dispersibility; surfactants and solubilizers can significantly improve this bottleneck. Polymers and cyclodextrins enhance solubility by forming inclusion complexes or solid dispersions. For sustained- and controlled-release formulations, excipients directly govern release behavior—the permeability of sustained-release matrix materials and coating films determines the rate and site of drug release. China's NMPA has cited erythromycin as an example: enteric coating prevents the drug from being destroyed by gastric acid and allows release only in the alkaline environment of the intestine, eliminating the need for patients to simultaneously take sodium bicarbonate tablets.

In terms of safety, the impact of excipients cannot be overlooked. Historically, both the "Qiqihar No. 2 Pharmaceutical" incident and the "chromium-exceeding capsule" incident originated from excipient quality problems—rooted in failures at the excipient stage. In the late 1960s, Australian epilepsy patients developed toxicity after taking phenytoin capsules because calcium sulfate used as a diluent was replaced with lactose—a seemingly "harmless" change that significantly altered the drug's release behavior. These cases reinforce a core principle: excipient changes are never trivial, and their functionality and safety must be rigorously evaluated.

Contact Us

For further information on pharmaceutical excipient products and technical support, please contact:

· Phone: +86-717-6253829

· Mobile / WhatSAPP: +86-150-5885-4156